Medtronic plc (MDT): Among the Best Dividend Aristocrat Stocks with Over 3% Yield
We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to ...
Prediction: Buying Medtronic Today Will Set You Up for Life
Medtronic's stock has lost around a third of its value since late 2022. However, stock prices for longtime dividend growers ...
MassDevice4h
Boston Scientific Farapulse PFA system shows superiority in head-to-head study with Medtronic cryoablation system
Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...
Medtronic shares trade in green after seven straight days of losses
Medtronic (NYSE:MDT) shares snapped seven straight days of losses as the stock closed 0.85% higher, at $88.98 on Thursday. ...
MassDevice1d
Medtronic says Evolut TAVR shows durable five-year outcomes in low-risk patients
Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...
Medtronic ventilators helped save lives during the pandemic, so why is the company shutting down the business?
Medtronic’s top ventilator executive began fielding pleas from world leaders' representatives five years ago, as pressure ...
Medtronic Evolut TAVR system show durable clinical outcomes
Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...
FDA classifies recall of Medtronic embolization devices as 'most serious'
The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", ...
Zacks Investment Research on MSN3d
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
Medtronic (MDT) closed the latest trading day at $88.98, indicating a +0.85% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 0.33%.
Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...
Medtronic: A Great Business, But With Low Growth
Medtronic’s diverse portfolio faces financial growth concerns. Learn why MDT stock is a HOLD, offering stability but limited growth in the short term.
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...